George A. Fisher Jr.
Academic Appointments
- Associate Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Stanford Cancer Center 875 Blake Wilbur Dr MC 5826 Stanford, CA 94305 Tel Work (650) 725-9057 Fax (650) 736-1373
- Academic Offices
Personal Information Email Tel (650) 725-9057Alternate Contact Diane Ayala Administrative Assistant Email Tel Work 650-725-9057Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> GI Oncology
- Medical Oncology
- Oncology
Administrative Appointments
- Physician Leader, GI Oncology Disease Management Group (2011 - present)
- Physician Leader, GI Clinical Research Group (2010 - present)
- Director, Cancer Clinical Trials Office (2004 - present)
Professional Education
| Fellowship: | Stanford University Medical Center CA (1993) |
| Residency: | Stanford University Medical Center CA (1989) |
| Internship: | Stanford University Medical Center CA (1988) |
| Medical Education: | Stanford University School of Medicine CA (1987) |
| BS: | Stanford University, Biology (1976) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
The research program focuses on clinical trials involving new investigational agents for the treatment of a wide range of cancers. Active clinical trials include studies involving doxorubicin and taxol and agents that reverse resistance to these drugs, such as PSC 833.
Other interests include phase I and II studies using anti-sense DNA, targeting PKC-alpha in ovarian cancer and the role of gene-modified autologous T cells engineered to recognize the TAG-72 antigen on colon cancer cells.
Clinical Trials
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Recruiting
- Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma Recruiting
- Vaccine Study for Surgically Resected Pancreatic Cancer Recruiting
- Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct Recruiting
- Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy Recruiting
Publications
- HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012; (1): 13-24
- 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nucl Med Commun. 2011; (5): 343-7
- A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011
- A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Invest New Drugs. 2011
- Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011; (7): 934-43
Help